New technological advances that allow the measurement of allelic imbalances in a more precise and informative manner will be of substantial importance to provide a definitive answer to the real extent of ASE at TGFBR1 in CRC patients. The gene discussed is TGFBR1; the disease is colorectal carcinoma.